CN-401

Study objectives: Main study objectives Phase I ? To determine the safety and tolerability, maximum tolerated dose (MTD) and/or phase II recommended dose (RP2D) of CN401 in Chinese patients with relapsed or refractory non-Hodgkin's lymphoma (R/R NHL). Phase II ? According to the Lugano 2014 evaluation criteria, the independent review committee (IRC) evaluated the overall response rate (ORR) of CN401 in patients with R/R PTCL/NKTCL and confirmed the anti-tumor activity of CN401. Secondary study objectives Phase I ? To evaluate the pharmacokinetic (PK) characteristics of CN401 and its main metabolite IN0385 in patients with R/R NHL; ? To preliminarily observe the anti-tumor efficacy of CN401 in patients with R/R NHL [ORR and complete response rate (CR)]; Phase II ? The IRC evaluated the following endpoints related to response: progression-free survival (PFS), duration of response (DoR), CR and time to response (TTR); ? Further evaluate the safety and tolerability of CN401 in Chinese patients with R/R PTCL/NKTCL; ? Further evaluate the population PK characteristics of CN401 and its major metabolite IN0385 in Chinese patients with R/R PTCL/NKTCL.